Anti-inflammatory medications reduce depressive symptom severity and anhedonia in individuals with depression and elevated ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines ...

SYNLAB and ALCEDIAG recently launched the first blood test to assist in mental health diagnosis in France. The test is aimed at differentiating bipolar disorders from depression. The news may be ...

Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder (MDD) in a small trial, pointing to one possible path forward for a candidate ...

Inflammation is our body’s defense mechanism against phenomena it recognizes as foreign. However, as with any complicated defense system, errors may occur. Inflammation helps our body fight off ...

Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in ...

I was in my second year of medical school when Solomon Snyder, a professor of neuroscience at Johns Hopkins Medical School, presented to our class his revolutionary work in brain chemistry and ...